Trial Profile
Effects of 18F-AV1451 PET imaging in suncortical vascular impairment in patients with subcortical vascular cognitive impairment, Alzheimer's disease and normal controls
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2017
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Diagnostic use
- 24 Aug 2017 New trial record
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017